IL304190A - Anti-pd-l1 antibodies and their fusion proteins - Google Patents

Anti-pd-l1 antibodies and their fusion proteins

Info

Publication number
IL304190A
IL304190A IL304190A IL30419023A IL304190A IL 304190 A IL304190 A IL 304190A IL 304190 A IL304190 A IL 304190A IL 30419023 A IL30419023 A IL 30419023A IL 304190 A IL304190 A IL 304190A
Authority
IL
Israel
Prior art keywords
antibodies
fusion proteins
fusion
proteins
Prior art date
Application number
IL304190A
Other languages
English (en)
Hebrew (he)
Original Assignee
Palleon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palleon Pharmaceuticals Inc filed Critical Palleon Pharmaceuticals Inc
Publication of IL304190A publication Critical patent/IL304190A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL304190A 2021-01-06 2023-07-02 Anti-pd-l1 antibodies and their fusion proteins IL304190A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163134412P 2021-01-06 2021-01-06
PCT/US2022/011504 WO2022150521A1 (en) 2021-01-06 2022-01-06 Anti-pd-l1 antibodies and fusion proteins thereof

Publications (1)

Publication Number Publication Date
IL304190A true IL304190A (en) 2023-09-01

Family

ID=82357548

Family Applications (1)

Application Number Title Priority Date Filing Date
IL304190A IL304190A (en) 2021-01-06 2023-07-02 Anti-pd-l1 antibodies and their fusion proteins

Country Status (10)

Country Link
US (1) US20240067729A1 (cg-RX-API-DMAC7.html)
EP (1) EP4274614A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024501771A (cg-RX-API-DMAC7.html)
KR (1) KR20230131236A (cg-RX-API-DMAC7.html)
CN (1) CN116829188A (cg-RX-API-DMAC7.html)
AU (1) AU2022206264A1 (cg-RX-API-DMAC7.html)
CA (1) CA3173557A1 (cg-RX-API-DMAC7.html)
IL (1) IL304190A (cg-RX-API-DMAC7.html)
MX (1) MX2023008028A (cg-RX-API-DMAC7.html)
WO (1) WO2022150521A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7462560B2 (ja) 2018-01-03 2024-04-05 パレオン ファーマシューティカルズ インコーポレイテッド 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびそれらの使用方法
JP2023532021A (ja) * 2020-07-03 2023-07-26 パレオン ファーマシューティカルズ インコーポレイテッド プロテアーゼ感受性が低減された組換えシアリダーゼ、シアリダーゼ融合タンパク質、及びその使用方法
KR20230138473A (ko) * 2021-01-06 2023-10-05 팔레온 파마슈티칼스 인크. 시알리다제-her2-항체 융합 단백질들 및 이의 사용방법
CN120779021A (zh) * 2024-04-08 2025-10-14 菲鹏生物股份有限公司 抗体缀合物及其用途
EP4744681A1 (en) 2024-08-16 2026-05-20 Shanghai Bao Pharmaceuticals Co., Ltd. COMPLEX TARGETING TARGET CELLS AND ITS USE

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG170091A1 (en) * 2006-03-10 2011-04-29 Wyeth Corp Anti-5t4 antibodies and uses thereof
AR093984A1 (es) * 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
KR20150131208A (ko) * 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Cd8에의 항원 결합 구조체들
MA42971A (fr) * 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
EP3277320A4 (en) * 2015-03-30 2018-08-01 Stcube, Inc. Antibodies specific to glycosylated pd-l1 and methods of use thereof
WO2018231661A1 (en) * 2017-06-12 2018-12-20 Tianxin Wang Methods and reagents to treat tumor and cancer
CN109970857B (zh) * 2017-12-27 2022-09-30 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
JP7462560B2 (ja) * 2018-01-03 2024-04-05 パレオン ファーマシューティカルズ インコーポレイテッド 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびそれらの使用方法
EP3569618A1 (en) * 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
CN111606995B (zh) * 2019-06-04 2021-02-12 优睿赛思(武汉)生物科技有限公司 抗人pd-l1单克隆抗体及其应用
CN111763259B (zh) * 2020-09-03 2020-12-15 北京百奥赛图基因生物技术有限公司 抗cd40抗体及其用途

Also Published As

Publication number Publication date
AU2022206264A1 (en) 2023-07-20
EP4274614A4 (en) 2025-06-18
EP4274614A1 (en) 2023-11-15
CA3173557A1 (en) 2022-07-14
US20240067729A1 (en) 2024-02-29
JP2024501771A (ja) 2024-01-15
CN116829188A (zh) 2023-09-29
MX2023008028A (es) 2023-08-14
WO2022150521A1 (en) 2022-07-14
KR20230131236A (ko) 2023-09-12

Similar Documents

Publication Publication Date Title
EP3783035A4 (en) FUSION PROTEIN OF IFN AND ANTI-PD-L1 ANTIBODIES AND ITS USE
IL299238A (en) Anti-pd-1 antibodies and fusion proteins
EP4274614A4 (en) ANTI-PD-L1 ANTIBODIES AND CORRESPONDING FUSION PROTEINS
SI3972987T1 (sl) Antigen-specifična imunoterapija za covid-19 fuzijske proteine in postopki za uporabo
EP4010378A4 (en) ANTICCR8 MONOCLONAL ANTIBODIES AND USES THEREOF
EP4023671A4 (en) ANTI-PD-L1 NANOBODIES AND FC FUSION PROTEIN AND THEIR APPLICATION
IL260218A (en) Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
IL266230A (en) Antibodies directed against t-cell immunoglobulin and mucin protein 3 (tim-3)
EP3901175A4 (en) ANTI-CD73 MONOCLONAL ANTIBODY AND USE THEREOF
EP4126965A4 (en) ANTI-PD-L1 ANTIBODIES AND ANTI-PD-L1/IL10 FUSION PROTEINS
EP3958901A4 (en) Bi-functional humanized anti-c5 antibodies and factor h fusion proteins and uses thereof
SG11202006008WA (en) Anti-pd-l1 antibodies and uses thereof
IL278102A (en) Fusion proteins containing cd47 antibodies and cytokines
EP3988576A4 (en) MONOCLONAL ANTIBODY CYTOKINE FUSION PROTEIN DIMER AND ITS USE
EP4267612A4 (en) HUMANIZED ANTI-C5 ANTIBODIES AND FACTOR H FUSION PROTEINS AND THEIR USES
SMT202600020T1 (it) Anticorpi monoclonali anti-gprc5d e usi di essi
IL306074A (en) UPAR antibodies and fusion proteins with them
IL326224A (en) Antibody conjugates and fusion proteins
EP4410841A4 (en) ANTI-IL23 ANTIBODY FUSION PROTEIN AND USES THEREOF
IL306129A (en) Structures of antigen-binding proteins and antibodies and their uses
EP3901171A4 (en) HUMAN ANTI-TIM-3 MONOCLONAL ANTIBODY AND USE THEREOF
IL317849A (en) Anti-SLC34A2 monoclonal antibodies and their uses
IL321241A (en) Antibodies against the fusion protein (f) of metapneumovirus and their uses
EP3983450A4 (en) ANTI-PD-L1/ANTI-LAG-3 PROTEINS WITH MULTIPLE ANTIGEN BINDING AND METHODS FOR THEIR USE
EP3994180A4 (en) ANTIBODY-HER2-SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF